Drugs / Zoster Vaccine Recombinant, Adjuvanted
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03702231 | Dec 2018 → Sep 2020 | chronic lymphocytic leukemia/small lymphocytic lymphoma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05718037 Comparator | Aug 2023 → Jan 2024 | herpes zoster | Wuhan BravoVax Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zoster Vaccine Recombinant, Adjuvanted | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05718037 ↗ |
| Modality | Vaccine | “recombinant zoster vaccine (RZV)” PMID 35157769 ↗ Mar 2022 |
| Route | Intramuscular | “by intramuscular injection” NCT03702231 ↗ |